0514 GMT - Top Glove's earnings are on the cusp of a progressive recovery this year, UOB Kay Hian analyst Jack Goh says in a note. The glove maker is likely to benefit from U.S. tariff hikes, including the additional 10% levy on Chinese goods, he writes. That could entice U.S. distributors to stop importing medical gloves from Chinese producers and instead buy from Malaysian manufacturers such as Top Glove, he says. The current risk-reward tradeoff appears fair but still provides palatable upside based on 2026 valuations, he adds. UOB KH maintains the stock's hold rating and target price of MYR1.31. Shares last closed at MYR1.22. (amanda.lee@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 00:14 ET (05:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。